RAS oncogenes: weaving a tumorigenic web
Open accessThe DOI matches its Crossref record; 243 of the 243 references it cites were found in a registry or an index.
Abstract
RAS proteins are essential components of signalling pathways that emanate from cell surface receptors. Oncogenic activation of these proteins owing to missense mutations is frequently detected in several types of cancer. A wealth of biochemical and genetic studies indicates that RAS proteins control a complex molecular circuitry that consists of a wide array of interconnecting pathways. In this Review, we describe how RAS oncogenes exploit their extensive signalling reach to affect multiple cellular processes that drive tumorigenesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Obviously, the RAF-MEK-ERK pathway is not the only pathway controlled by KRAS, 18 which is supported by findings demonstrating enhanced efficacy of combining MEK inhibitors with phosphoinositide 3-kinase inhibitors in NSCLC models.19,20”
From K-ras Mutation Subtypes in NSCLC and Associated Co-occuring Mutations in Other Oncogenic Pathways (2019) · cites this paper as [18]
The cited source says what the claim attributes to it.
In the citing paper
“Mutations in G12, G13, or Q61 residue in the active site can lock KRAS in the GTP-bound form by impeding the hydrolysis to GDP catalyzed by GAPs, thus keeping downstream signaling constitutively active [16, 17].”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [17]
In the citing paper
“PDEδ has a large hydrophobic pocket that can bind farnesyl proteins, especially the lipid portion of KRAS protein, thereby preventing the farnesyl modification of KRAS protein from binding to cell membrane and inhibiting tumor cell proliferation and growth.339,340”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [340]
In the citing paper
“The resulting RAS-mediated signaling cascades drive tumor initiation, maintenance and progression by deregulating key cellular processes, for instance by increasing proliferation and suppressing apoptosis, but also by rewiring cellular metabolism and promoting alterations in the tumor microenvironment3.”
From The metabolic landscape of RAS-driven cancers from biology to therapy (2021) · cites this paper as [3]
In the citing paper
“By constitutively activating these pathways, the Ras oncoprotein confers growth, survival and metastatic advantages to the cancer cell (11).”
From KRAS mutation in pancreatic cancer (2021) · cites this paper as [11]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590 · cited 1×
“To accommodate the emergence of additional cancer-associated pathologies this list has been increased to include additional hallmarks such as metabolic fitness and genomic plasticit”
BackgroundHanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
Vander Heiden, M. G., Cantley, L. C., & Thompson, C. B. (2009) · Science · doi:10.1126/science.1160809 · Cited by 16,197
Warburg, O. (1956) · Science · doi:10.1126/science.123.3191.309 · Cited by 13,425 · cited 1×
“These unique metabolic needs were first described in the 1920s by Otto Warburg and are typified by an increase in glucose uptake and a shift from mitochondrial oxidative phosphorylation to aerobic glycolysi”
BackgroundAkt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery
Datta, S. R., Dudek, H., Tao, X., Masters, S., Fu, H., Gotoh, Y., & Greenberg, M. E. (1997) · Cell · doi:10.1016/s0092-8674(00)80405-5 · Cited by 5,689
ras oncogenes in human cancer: a review.
Bos, J. L. (1989) · PubMed · Cited by 5,061
Disruption of epithelial cell-matrix interactions induces apoptosis
Frisch, S., & Francis, H. (1994) · The Journal of cell biology · doi:10.1083/jcb.124.4.619 · Cited by 3,254
Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis
Bergers, G., Brekken, R., McMahon, G., Vu, T. H., Itoh, T., Tamaki, K., Tanzawa, K., Thorpe, P., Itohara, S., Werb, Z., et al. (2000) · Nature Cell Biology · doi:10.1038/35036374 · Cited by 2,797 · cited 1×
“Hence, the modification of the surrounding ECM is necessary both for the growth factors to reach the target endothelium and for the migration of the newly generated endothelium into the tumou”
BackgroundDNA damage response as a candidate anti-cancer barrier in early human tumorigenesis
Bartkova, J., Hořejší, Z., Koed, K., Krämer, A., Tort, F., Zieger, K., Guldberg, P., Sehested, M., Nesland, J. M., Lukas, C., et al. (2005) · Nature · doi:10.1038/nature03482 · Cited by 2,688 · cited 1×
“An inevitable consequence of the persistent mitogenic stimulation that is imposed by RAS is the initiation of replicative stress, which is marked by increased numbers of active DNA replication origins and collapsed replication forks, which ultimately leads to DNA damage and the activation of the DNA damage response (D…”
BackgroundPreinvasive and invasive ductal pancreatic cancer and its early detection in the mouse
Hingorani, S. R., Petricoin, E. F., Maitra, A., Rajapakse, V., King, C., Jacobetz, M. A., Ross, S., Conrads, T. P., Veenstra, T. D., Hitt, B. A., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00309-x · Cited by 2,471
Cited by
Items 801–900 of 1,003
Miao, C., Shen, Y., Lang, Y., Li, H., Gong, Y. Q., Liu, Y., Li, H., Jones, B. C., Chen, F., & Feng, S. (2024) · Theranostics · doi:10.7150/thno.95614 · Cited by 25
“Interestingly, cluster 3 is associated with the Ras signaling pathway and MAPK signaling pathway, which was associated with cell apoptosis [40].”
BackgroundKu, B. M., Jho, E. H., Bae, Y.-H., Sun, J., Ahn, J. S., Park, K., & Ahn, M. (2014) · Investigational New Drugs · doi:10.1007/s10637-014-0163-9 · Cited by 26
NRAS Mutant Melanoma: An Overview for the Clinician for Melanoma Management
Jenkins, R. W., & Sullivan, R. J. (2016) · Melanoma Management · doi:10.2217/mmt.15.40 · Cited by 28
Christensen, S. M., Triplet, M. G., Rhodes, C., Iwig, J. S., Tu, H., Stamou, D. G., & Groves, J. T. (2016) · Nano Letters · doi:10.1021/acs.nanolett.6b00969 · Cited by 25
The ability of endogenous Nras oncogenes to initiate leukemia is codon-dependent
Kong, G., Chang, Y.-I., You, X., Ranheim, E. A., Zhou, Y., Burd, C. E., & Zhang, J. (2016) · Leukemia · doi:10.1038/leu.2016.89 · Cited by 25
Michael, J. V., Wurtzel, J. G. T., & Goldfinger, L. E. (2016) · Oncogenesis · doi:10.1038/oncsis.2016.36 · Cited by 26
Park, J. H., Gurunathan, S., Choi, Y., Han, J. W., Song, H., & Kim, J. (2016) · Journal of Industrial and Engineering Chemistry · doi:10.1016/j.jiec.2016.11.015 · Cited by 25
Common mechanisms of catalysis in small and heterotrimeric GTPases and their respective GAPs
Gerwert, K. B., Mann, D., & Kötting, C. (2017) · Biological Chemistry · doi:10.1515/hsz-2016-0314 · Cited by 27
“Importantly, mutations that interfere with GTP hydrolysis are frequent in various tumors (Pylayeva-Gupta et al., 2011; O’Hayre et al., 2013) and fibrous dysplasia (Dumitrescu and Collins, 2008).”
BackgroundPhylogenetic analysis of the SINA/SIAH ubiquitin E3 ligase family in Metazoa
Pepper, I., Sciver, R. E. V., & Tang, A. (2017) · BMC Evolutionary Biology · doi:10.1186/s12862-017-1024-x · Cited by 25
C/EBPβ deletion in oncogenic Ras skin tumors is a synthetic lethal event
Messenger, Z. J., Hall, J. R., Jima, D. D., House, J. S., Tam, H. W., Tokarz, D. A., & Smart, R. C. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-1103-y · Cited by 26
Zhang, Y., Wang, Z., Ma, X., Yang, S., Hu, X., Tao, J., Hou, Y., & Bai, G. (2018) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2018.11.002 · Cited by 25
Molecular profiling of clear cell adenocarcinoma of the urinary tract
Lin, C., Saleem, A., Stehr, H., Zehnder, J. L., Pinsky, B. A., & Kunder, C. A. (2019) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-019-02634-5 · Cited by 27
Li, L., Fan, Y., Huang, X., Luo, J., Zhong, L., Shu, X., Lu, L., Xiang, T., Chan, A. T. �., Yeo, W., et al. (2019) · iScience · doi:10.1016/j.isci.2019.10.007 · Cited by 27
RetractedGrzes, M., Oroń, M., Staszczak, Z., Jaiswar, A., Nowak-Niezgoda, M., & Walerych, D. (2020) · Cancers · doi:10.3390/cancers12061532 · Cited by 26
Ma, Z., Zhou, M., Shen, Q., & Zhou, J. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c01441 · Cited by 31
Tomino, T., Tajiri, H., Tatsuguchi, T., Shirai, T., Oisaki, K., Matsunaga, S., Sanematsu, F., Sakata, D., Yoshizumi, T., Maehara, Y., et al. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.02.073 · Cited by 24
Treatment of KRAS-Mutated Pancreatic Cancer: New Hope for the Patients?
Krupa, K., Fudalej, M. M., Włoszek, E., Miski, H., Badowska-Kozakiewicz, A. M., Mękal, D., Budzik, M. P., Czerw, A. I., & Deptała, A. (2025) · Cancers · doi:10.3390/cancers17152453 · Cited by 25
Thaler, R., Spitzer, S. G., Karlic, H., Berger, C., Klaushofer, K., & Varga, F. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.10.016 · Cited by 25
Doi, A., Kita, A., Kanda, Y., Uno, T., Asami, K., Satoh, R., Nakano, K., & Sugiura, R. (2015) · Genes to Cells · doi:10.1111/gtc.12222 · Cited by 24
“In higher eucaryotes, the Ras superfamily of small GTPases is frequently active in cancer and thus an attractive target for cancer therapy (Pylayeva-Gupta et al. 2011).”
BackgroundKwon, S.-J., Kwon, O., Kim, K.-T., Go, Y.-H., Yu, S.-I., Lee, B., Miyoshi, H., Oh, E., Cho, S.-J., & Cha, H. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0703-y · Cited by 24
“Although RAS, a downstream effector of EGFR, is one of the most frequently mutated oncogenes in many types of cancer [18], mutations of RAS in glioma are relatively rare [19].”
Autoactivation of small GTPases by the GEF–effector positive feedback modules
Goryachev, A. B., & Leda, M. (2019) · F1000Research · doi:10.12688/f1000research.20003.1 · Cited by 25
Nakayama, A., Nagashima, T., Nishizono, Y., Kuramoto, K., Mori, K., Homboh, K., Yuri, M., & Shimazaki, M. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01629-x · Cited by 25
“Most KRAS missense mutations occur at codon 12 in the P-loop [4] and cause resistance to GAP-catalysed hydrolysis and accelerate downstream signalling [3, 5, 6].”
BackgroundRoof, A. K., Trudeau, T., Gomez, C. L., Lucia, M. S., & Gutierrez‐Hartmann, A. (2014) · Molecular Endocrinology · doi:10.1210/me.2014-1168 · Cited by 24
The dynamics of the catalytic site in small GTPases, variations on a common motif
Kötting, C., & Gerwert, K. B. (2013) · FEBS Letters · doi:10.1016/j.febslet.2013.05.021 · Cited by 31
1H, 13C and 15N resonance assignment for the human K-Ras at physiological pH
Vo, U., Embrey, K. J., Breeze, A. L., & Golovanov, A. P. (2012) · Biomolecular NMR Assignments · doi:10.1007/s12104-012-9413-y · Cited by 25
“In contrast, the inactive Ras GDP cannot bind downstream effector proteins (Downward 2003; Pylayeva-Gupta et al. 2011).”
BackgroundAn adenovirus-derived protein: A novel candidate for anti-diabetic drug development
Hegde, V. K., Na, H.-N., Dubuisson, O. S., Burke, S. J., Collier, J. J., Burk, D. H., Mendoza, T. M., & Dhurandhar, N. V. (2015) · Biochimie · doi:10.1016/j.biochi.2015.12.002 · Cited by 24
“Given the potential role of Ras in tumorogenesis [38], the in vivo effect of E4orf1 requires careful investigation.”
Madureira, P. A., Bharadwaj, A. G., Bydoun, M., Garant, K. A., O'Connell, P., Lee, P. C., & Waisman, D. M. (2016) · Oncotarget · doi:10.18632/oncotarget.10279 · Cited by 24
“Oncogenic HRAS mediates the upregulation of MMP2 and MMP9 which play a key role in degrading the extracellular matrix [37].”
BackgroundInfluentialSensitive detection of cancer gene based on a nicking-mediated RCA of circular DNA nanomachine
Wang, Z.-Y., Li, F., Zhang, Y., Zhao, H., Xu, H. Y., Wu, Z., Lyu, J., & Shen, Z. (2017) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2017.05.061 · Cited by 24
Multi-omics Signatures and Translational Potential to Improve Thyroid Cancer Patient Outcome
Boufraqech, M., & Nilubol, N. (2019) · Cancers · doi:10.3390/cancers11121988 · Cited by 27
Joshi, S., Gomes-DaGama, E. M., Wang, T., Corben, A. D., Taldone, T., Gandu, S. R., Xu, C., Sharma, S., Buddaseth, S., Yan, P., et al. (2021) · Communications Biology · doi:10.1038/s42003-021-02842-3 · Cited by 24
Lin, J. C., Chou, C., Gao, S., Wu, S., Khoo, K., & Lin, C. (2013) · ChemBioChem · doi:10.1002/cbic.201300050 · Cited by 24
Liu, Y., Li, H., Zhu, J., Zhang, Y., Liu, X., Li, R., Zhang, Q., & Cheng, Y. (2021) · Cancer Management and Research · doi:10.2147/cmar.s282617 · Cited by 23
Emerging RAS-directed therapies for cancer
Conroy, M. R., Cowzer, D., Kölch, W., & Duffy, A. G. (2021) · Cancer Drug Resistance · doi:10.20517/cdr.2021.07 · Cited by 26
Identification of Potential Core Genes in Parkinson’s Disease Using Bioinformatics Analysis
Quan, W., Li, J., Jin, X., Liu, L., Zhang, Q., Qin, Y., Pei, X., & Chen, J. (2021) · Parkinson s Disease · doi:10.1155/2021/1690341 · Cited by 33
“HRAS is a member of the RAS oncogene family, and its mutations are common in a variety of cancers, including head and neck cancer, skin cancer, and hematopoietic cancers [17, 18].”
BackgroundPan-RAS inhibitors: Hitting multiple RAS isozymes with one stone
Coley, A. B., Ward, A., Keeton, A. B., Chen, X., Maxuitenko, Y. Y., Prakash, A., Li, F., Foote, J. B., Buchsbaum, D. J., & Piazza, G. A. (2022) · Advances in cancer research · doi:10.1016/bs.acr.2021.07.009 · Cited by 27
Segeren, H. A., van Liere, E. A., Riemers, F. M., de Bruin, A., & Westendorp, B. (2022) · Oncogene · doi:10.1038/s41388-022-02291-0 · Cited by 24
“Hyperactivation of the MAPK pathway by mutations in one of the RAS isoforms is one of the most frequent alterations in human malignancies [24].”
BackgroundMouse models of Kras activation in gastric cancer
Won, Y., & Choi, E.-Y. K. (2022) · Experimental & Molecular Medicine · doi:10.1038/s12276-022-00882-1 · Cited by 28
Li, X., Jie, Q., Zhang, H., Zhao, Y., Lin, Y., Du, J., Shi, J., Wang, L., Guo, K. X., Li, Y., et al. (2016) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2016.05.008 · Cited by 23
Significance of Ras Signaling in Cancer and Strategies for its Control
Gurung, A. B., Bhattacharjee, A., & Researcher (2015) · touchREVIEWS in Oncology & Haematology · doi:10.17925/ohr.2015.11.02.147 · Cited by 29
Click-Chemistry Based High Throughput Screening Platform for Modulators of Ras Palmitoylation
Ganesan, L., Shieh, P., Bertozzi, C. R., & Levental, I. (2017) · Scientific Reports · doi:10.1038/srep41147 · Cited by 23
Chuang, L. S. H., Ito, K., & Ito, Y. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-981-10-3233-2_19 · Cited by 24
Induction of N-Ras degradation by flunarizine-mediated autophagy
Zheng, Z.-Y., Li, J., Li, F., Zhu, Y., Cui, K., Wong, S. T. C., Chang, E. C., & Liao, Y. (2018) · Scientific Reports · doi:10.1038/s41598-018-35237-2 · Cited by 23
Oncogenic role of TYRO3 receptor tyrosine kinase in the progression of pancreatic cancer
Morimoto, M., Horikoshi, Y., Nakaso, K., Kurashiki, T., Kitagawa, Y., Hanaki, T., Sakamoto, T., Honjo, S., Umekita, Y., Fujiwara, Y., et al. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.11.028 · Cited by 24
Gong, B., Kao, Y., Zhang, C., Zhao, H., Sun, F., & Gong, Z. (2019) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2019/2735050 · Cited by 23
“RAS protein mutations could result in nonreversible reduction in GTPase activity or inability of activating GTPase [40], and mutations in KRAS held about 85% of overall RASmutations in human tumors; NRAS about 15%; and HRAS less than 1% [41]. e probability of KRAS mutation was approximately 30–50% in CRC [42], associa…”
BackgroundGagan, G., Lee, D. C., Guye, M. L., Sciver, R. E. V., Lee, P., Lafever, A., Anthony, P., Tang-Tan Angela, M., Winston, J. S., Şamli, B., et al. (2020) · Annals of Breast Cancer and Therapy · doi:10.36959/739/525 · Cited by 25
Song, Y., Sun, X., Duan, F., He, C., Wu, J., Huang, X., Xing, K., Sun, S., Wang, R., Xie, F., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01482 · Cited by 23
Primary Sclerosing Cholangitis and Cholangiocarcinoma: Pathogenesis and Modes of Diagnostics
Ehlken, H., & Schramm, C. (2013) · Digestive Diseases · doi:10.1159/000347206 · Cited by 24
Hu, S., Han, Y., Tan, T.-Y., Chen, H., Gao, J.-W., Wang, L., Yang, M., Zhao, L., Wang, Y., Ding, Y., et al. (2023) · JCI Insight · doi:10.1172/jci.insight.167874 · Cited by 27
Nohara, K., Okamura, K., Suzuki, T., Murai, H., Ito, T., Shinjo, K., Takumi, S., Michikawa, T., Kondo, Y., & Hata, K. (2015) · Journal of Applied Toxicology · doi:10.1002/jat.3149 · Cited by 22
“Ha-ras mutation is thought to be involved in carcinogenesis by activating several signaling pathways, including the RAF/MEK/ERK cascade (Pylayeva-Gupta et al., 2011).”
BackgroundThe greedy nature of mutant RAS: a boon for drug discovery targeting cancer metabolism?
Lv, J., Wang, J., Chang, S., Liu, M., & Pang, X. (2015) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmv102 · Cited by 23
Hara, T., Jones, M. F., Subramanian, M., Li, X. L., Ou, O. L., Zhu, Y. J., Yang, Y.-A., Wakefield, L. M., Hussain, S. P., Gaedcke, J., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2284 · Cited by 23
“Activating mutations in KRAS including G12D and G13D lock KRAS in the GTP-bound, constitutively active state to deregulate multiple downstream pathways resulting in deregulated cell growth, evasion from apoptosis and angiogenesis [21-23].”
Cancer signaling: when phosphorylation meets methylation
Ying, H., & DePinho, R. A. (2014) · Cell Research · doi:10.1038/cr.2014.103 · Cited by 22
Personalized treatment for colorectal cancer: novel developments and putative therapeutic strategies
Akkad, J., Bochum, S., & Martens, U. M. (2015) · Langenbeck s Archives of Surgery · doi:10.1007/s00423-015-1276-0 · Cited by 24
Caiola, E., Brunelli, L., Marabese, M., Broggini, M., Lupi, M., & Pastorelli, R. (2016) · Oncotarget · doi:10.18632/oncotarget.9849 · Cited by 22
“KRAS signaling is highly complex and dynamic, engaging various downstream effectors, such as canonical Raf/Mek/Erk and PI3K/akt/mTOR signaling networks [9, 10].”
Inhibition of Galectin-1 Sensitizes HRAS-driven Tumor Growth to Rapamycin Treatment
Michael, J. V., Wurtzel, J. G. T., & Goldfinger, L. E. (2016) · Anticancer Research · doi:10.21873/anticanres.11074 · Cited by 22
Komatsu, H., Iguchi, T., Masuda, T., Hirata, H., Ueda, M., Kidogami, S., Ogawa, Y., Sato, K., Hu, Q., Nambara, S., et al. (2016) · Annals of Surgical Oncology · doi:10.1245/s10434-016-5573-9 · Cited by 22
Jia, Z., Liu, W., Gong, L., & Xiao, Z. (2017) · Oncology Letters · doi:10.3892/ol.2017.5581 · Cited by 22
“Previous studies have demonstrated that mutation of RAS genes is the primary mechanism of aberrant RAS activation (8,20,21).”
BackgroundHashikawa, K.-I., Katamune, C., Kusunose, N., Matsunaga, N., Koyanagi, S., & Ohdo, S. (2017) · Scientific Reports · doi:10.1038/s41598-017-10599-1 · Cited by 22
Dovrat, T. O., Sokol, E. S., Frampton, G. M., Shachar, E. K., Pelles, S., Geva, R., & Wolf, I. (2018) · Cancer Biology & Therapy · doi:10.1080/15384047.2018.1480289 · Cited by 25
Small Molecule SOS1 Agonists Modulate MAPK and PI3K Signaling via Independent Cellular Responses
Akan, D. T., Howes, J. E., Sai, J., Arnold, A. L., Beesetty, Y., Phan, J., Olejniczak, E. T., Waterson, A. G., & Fesik, S. W. (2019) · ACS Chemical Biology · doi:10.1021/acschembio.8b00869 · Cited by 22
Rozengurt, E., & Eibl, G. (2019) · World Journal of Gastroenterology · doi:10.3748/wjg.v25.i15.1797 · Cited by 22
Jang, S. I., Fang, S., Baek, Y.-Y., Lee, D. H., Na, K., Lee, S. Y., & Lee, S. Y. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21051605 · Cited by 22
Lu, H., & Martí, J. (2020) · The Journal of Physical Chemistry Letters · doi:10.1021/acs.jpclett.0c02809 · Cited by 23
Suppression of the HBP Function Increases Pancreatic Cancer Cell Sensitivity to a Pan-RAS Inhibitor
Ricciardiello, F., Bergamaschi, L., Vitto, H. D., Yang, G., Zhang, T., Palorini, R., & Chiaradonna, F. (2021) · Cells · doi:10.3390/cells10020431 · Cited by 23
Hydrophobic Tagging-Induced Degradation of PDEδ in Colon Cancer Cells
Guo, M., He, S., Cheng, J., Li, Y., Dong, G., & Sheng, C. (2022) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.1c00670 · Cited by 22
Urbanelli, L., Magini, A., Ercolani, L., Sagini, K., Polchi, A., Tancini, B., Brozzi, A., Armeni, T., Principato, G., & Emiliani, C. (2014) · PLoS ONE · doi:10.1371/journal.pone.0089485 · Cited by 23
“as molecular switches to transmit extracellular signals inside the cell and it is frequently mutated in different human cancers [6,7].”
BackgroundSciver, R. E. V., Lee, M., Lee, C., Lafever, A., Svyatova, E. A., Kanda, K., Collier, A. L., van Reesema, L. L. S., Tang-Tan, A. M., Zheleva, V. P., et al. (2018) · Cancers · doi:10.3390/cancers10050142 · Cited by 21
Genetic Screens Identify a Context-Specific PI3K/p27Kip1 Node Driving Extrahepatic Biliary Cancer
Falcomatà, C., Bärthel, S., Ulrich, A., Diersch, S., Veltkamp, C., Rad, L., Boniolo, F., Solar, M., Steiger, K., Seidler, B., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0209 · Cited by 21
“This mouse line carries a glycine (G) to aspartic acid (D) mutation at codon 12 (G12D) of Kras, which is refractory to GTPase-activating protein (GAP)–induced GTP hydrolysis, favoring an active state (26).”
H-Ras regulation of TRAIL death receptor mediated apoptosis
Chen, J., Bozza, W. P., Di, X. M., Zhang, Y., Hallett, W. H. D., & Zhang, B. (2014) · Oncotarget · doi:10.18632/oncotarget.2091 · Cited by 21
“This distinct function of H-Ras is intriguing given that K-Ras and other isoforms are nearly identical with respect to their catalytic and effector-binding properties [38].”
InfluentialSuzuki, T., Yamashita, S., Ushijima, T., Takumi, S., Sano, T., Michikawa, T., & Nohara, K. (2013) · Cancer Science · doi:10.1111/cas.12298 · Cited by 21
Sartor, I. T. S., Zeidán‐Chuliá, F., Albanus, R. D., Dalmolin, R. J. S., & Moreira, J. C. F. (2014) · Molecular BioSystems · doi:10.1039/c3mb70590k · Cited by 21
Ras Effector Mutant Expression Suggest a Negative Regulator Inhibits Lung Tumor Formation
Vandal, G., Geiling, B., & Dankort, D. L. (2014) · PLoS ONE · doi:10.1371/journal.pone.0084745 · Cited by 24
“The protein products of KRAS (KRAS 4A and KRAS 4B) are small GTPases of 21 kDa that serve as molecular switches for signal transduction from the cellular membrane, by alternating between an active, GTP-bound state and an inactive GDP-bound conformation [18,19].”
BackgroundKRAS Mutant Tumor Subpopulations can Subvert Durable Responses to Personalized Cancer Treatments
Parsons, B. L., & Myers, M. B. (2013) · Personalized Medicine · doi:10.2217/pme.13.1 · Cited by 22
The role of the NORE1A tumor suppressor in Oncogene-Induced Senescence
Barnoud, T., Schmidt, M., Donninger, H., & Clark, G. J. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.04.030 · Cited by 27
“Pro-mitogenic pathways controlled by Ras are regulated by numerous effector proteins, such as the Raf kinases and PI3-kinase (25,26).”
Nishizawa, T., Nakano, K., Harada, A., Kakiuchi, M., Funahashi, S., Suzuki, M., Ishikawa, S., & Aburatani, H. (2018) · Oncotarget · doi:10.18632/oncotarget.25269 · Cited by 21
Yang, T., Yang, W., Li, J., Tan, T., Yang, J., Pan, J., Hu, C., Yao, Y., Zhang, J., Xin, Y., et al. (2019) · Experimental Hematology and Oncology · doi:10.1186/s40164-019-0135-z · Cited by 21
Efficacy of immunotherapy in KRAS -mutant non-small-cell lung cancer with comutations
Davis, A. P., Cooper, W. A., Boyer, M. J., Lee, J., Pavlakis, N., & Kao, S. (2021) · Immunotherapy · doi:10.2217/imt-2021-0090 · Cited by 21
Decreased tumorigenesis in mice with a Kras point mutation at C118
Huang, L., Carney, J., Cardona, D. M., & Counter, C. M. (2014) · Nature Communications · doi:10.1038/ncomms6410 · Cited by 22
“Kras was chosen, as this is the isoform most commonly mutated in human cancers 1 .”
Neurofibromin: Protein Domains and Functional Characteristics
Scheffzek, K., & Welti, S. (2012) · Springer eBooks · doi:10.1007/978-3-642-32864-0_20 · Cited by 24
“The physiological impact of Ras regulation is underscored by the notion that Ras is mutated in a large number of human malignancies and many of the respective mutants are unable to hydrolyse GTP at a rate sufficient to terminate downstream signaling and are GAP-insensitive (Trahey and McCormick 1987; Bos et al. 1987;…”
BackgroundChen, X., Zou, F., Hu, Z., Du, G., Yu, P., Wang, W., Wang, H., Ye, L., & Tian, J. (2020) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2020.115019 · Cited by 20
Sacco, A., Federico, C., Todoerti, K., Ziccheddu, B., Palermo, V., Giacomini, A., Ravelli, C., Maccarinelli, F., Bianchi, G., Belotti, A., et al. (2021) · Blood · doi:10.1182/blood.2020010572 · Cited by 20
Advancements in gene therapies targeting mutant KRAS in cancers
Wang, Y., Bui, T. A., Yang, X., Hutvágner, G., & Deng, W. (2025) · Cancer and Metastasis Reviews · doi:10.1007/s10555-025-10243-9 · Cited by 23
“Apart from driving tumourigenesis, mutant KRAS can also affect the tumour microenvironment (TME) by regulating cytokine release, recruitment of immune cells to the tumour sites for enhanced inflammatory responses as well as facilitating immune escape [27, 28].”
Marasco, M., Kumar, D., Borrego, S. G., Seale, T. S., Maddalena, G., Mezzadra, R., Belanger, K., Cole, S., Perez, B., Luan, W., et al. (2025) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0614 · Cited by 21
Matsushita, J., Okamura, K., Nakabayashi, K., Suzuki, T., Horibe, Y., Kawai, T., Sakurai, T., Yamashita, S., Higami, Y., Ichihara, G., et al. (2018) · BMC Cancer · doi:10.1186/s12885-018-4221-0 · Cited by 20
“These somatic mutations activate Ras proteins and lead to activation of tumor augmenting pathways, including the RAF/MEK/ERK kinase cascade [7].”
BackgroundKaraboga, H., Huang, W., Srivastava, S., Widmann, S., Addanki, S., Gamage, K. T., Mazhar, Z., Ebalunode, J. O., Briggs, J. M., Gustafsson, J.-Α., et al. (2020) · ACS Chemical Biology · doi:10.1021/acschembio.0c00546 · Cited by 21
Dehner, C. A., Armstrong, A. E., Yohe, M. E., Shern, J. F., & Hirbe, A. C. (2021) · Genes · doi:10.3390/genes12101500 · Cited by 21
Pancreatic Tumorigenesis: Precursors, Genetic Risk Factors and Screening
Badheeb, M. A., Abdelrahim, A., Esmail, A., Umoru, G., Abboud, K., Al-Najjar, E., Rasheed, G. O., Alkhulaifawi, M., Abudayyeh, A., & Abdelrahim, M. (2022) · Current Oncology · doi:10.3390/curroncol29110686 · Cited by 23
A High-Throughput Assay for Small Molecule Destabilizers of the KRAS Oncoprotein
Carver, J. O., Dexheimer, T. S., Hsu, D. J., Weng, M., Smith, J. L., Guha, R., Jadhav, A., Simeonov, A. M., & Luo, J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0103836 · Cited by 20
Anti-EGFR Therapy: Strategies in Head and Neck Squamous Cell Carcinoma
Oliveira, R. J. D. S., de Carvalho, A. C., Viana, L. D. S., Carvalho, A. L., & Reis, R. M. (2016) · Recent Patents on Anti-Cancer Drug Discovery · doi:10.2174/1574892811666160309121238 · Cited by 21
“However, KRAS mutations result in incessant activation of the intracellular RAS/MAPK/PI3K pathways, resulting in increased cell proliferation and survival, neoplastic transformation, cell migration and metastasis [143].”
BackgroundMolecular Genetics of Pancreatic Neoplasms
Hosoda, W., & Wood, L. D. (2016) · Surgical pathology clinics · doi:10.1016/j.path.2016.05.011 · Cited by 21
Wu, M. H., Huang, J., Zhang, J., Benes, C. H., Jiao, B., & Ren, R. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0419 · Cited by 21
“Because the biological activity of RAS proteins relies upon lipid modifications and RAS regulates lipid metabolisms in cancer cells (21), we screened a bioactive lipid library with a RAS-specific cell viability assay for potential therapeutics against RAS-driven cancer.”
BackgroundMethodMultiple components of PKA and TGF-β pathways are mutated in pseudomyxoma peritonei
Saarinen, L., Nummela, P., Thiel, A., Lehtonen, R., Järvinen, P., Järvinen, H., Aaltonen, L. A., Lepistö, A., Hautaniemi, S., & Ristimaki, A. P. (2017) · PLoS ONE · doi:10.1371/journal.pone.0174898 · Cited by 23
Isoprenyl carboxyl methyltransferase inhibitors: a brief review including recent patents
Yang, W. S., Yeo, S., Yang, S., Kim, K., Yoo, B. C., & Cho, J. Y. (2017) · Amino Acids · doi:10.1007/s00726-017-2454-x · Cited by 20
Survivin knockdown induces senescence in TTF‑1-expressing, KRAS-mutant lung adenocarcinomas
Sumi, T., Hirai, S., Yamaguchi, M., Tanaka, Y., Tada, M., Yamada, G., Hasegawa, T., Miyagi, Y., Niki, T., Watanabe, A., et al. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4365 · Cited by 20
“Constitutively activated mutant KRAS protein has been proven to be notoriously difficult to target with small molecule inhibitors, and this has led to the use of trametinib and selumetinib, two MEK (MAPK/ERK kinase) inhibitors, as promising candidates in the treatment of KRAS-mutant cancer (5,6).”
A H-REV107 Peptide Inhibits Tumor Growth and Interacts Directly with Oncogenic KRAS Mutants
Han, C. W., Jeong, M. S., Ha, S. C., & Jang, S. B. (2020) · Cancers · doi:10.3390/cancers12061412 · Cited by 20
Lee, S., Heinrich, E. L., Lu, J., Lee, W., Choi, A. H., Luu, C., Chung, V. M., Fakih, M., & Kim, J. (2015) · Pancreas · doi:10.1097/mpa.0000000000000379 · Cited by 26
“More than 90% of patients with pancreatic cancer harbor similar somatic mutations in K-ras, which result in constitutively active protein product.(33) Signals from upstream receptor tyrosine kinases are transmitted by K-ras to downstream MAPK pathway effectors.”
BackgroundGutiérrez‐Salmerón, M. T., Chocarro‐Calvo, A., García-Martínez, J. M., la Vieja, A. D., & García‐Jiménez, C. (2017) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2016.10.005 · Cited by 24
Epidemiological bases and molecular mechanisms linking obesity, diabetes, and cancer
Gutiérrez-Salmerón, M., Chocarro‐Calvo, A., García-Martínez, J. M., la Vieja, A. D., & García‐Jiménez, C. (2017) · Endocrinología Diabetes y Nutrición (English ed ) · doi:10.1016/j.endien.2016.10.002 · Cited by 22
Yoshida, M., Taguchi, A., Kawana, K., Ogishima, J., Adachi, K., Kawata, A., Nakamura, H., Sato, M., Fujimoto, A., Inoue, T., et al. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4504 · Cited by 20
“We herein propose that the increased number of neutrophils in KRAS-induced ascites possessed antitumor properties by modulating the TME, and that this effect was more potent in KRAS-associated neutrophils.”
BackgroundInfluentialPeralta, S., McCleary‐Wheeler, A. L., Duhamel, G. E., Heikinheimo, K., & Grenier, J. K. (2019) · Veterinary and Comparative Oncology · doi:10.1111/vco.12487 · Cited by 20
Metadata
- Authors
- Pylayeva-Gupta, Y., Grabocka, E., & Bar-Sagi, D.
- Affiliations
- New York University (US)
- ORCID
- Grabocka, Elda
- Venue
- Nature Reviews Cancer
- Published
- 2011-10-13
- Volume
- 11
- Issue
- 11
- Pages
- 761-774
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- PMC
- PMC3632399
- OpenAlex
- W1970527559
- Cited by
- 1,789
- References
- 239
- Citations by year
- 2026: 78 · 2025: 95 · 2024: 108 · 2023: 109 · 2022: 123 · 2021: 154 · 2020: 113 · 2019: 144 · 2018: 124 · 2017: 143 · 2016: 156 · 2015: 139 · 2014: 123 · 2013: 111 · 2012: 59
- FWCI
- 8.51
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Cancer Research Institute
- National Cancer Institute (R01CA055360, 1F32CA13922, CA 055360, R37CA055360, R56CA055360)
- National Institute of General Medical Sciences (R01GM078266, GM078266)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- oncogenic Ras, oncogenic Ras mutations, carcinogenesis, Ras isoforms, missense mutations, cell-autonomous effects, non-cell-autonomous effects, signaling pathways, cancer
- MeSH terms
- Animals, Cell Transformation, Neoplastic, Humans, Neoplasm Metastasis, Genes, ras, Apoptosis, Mutation, Missense, Cell Proliferation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.